Innate Pharma (IPHA) Common Equity (2017 - 2019)

Innate Pharma (IPHA) has disclosed Common Equity for 3 consecutive years, with $240.7 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Common Equity rose 26.07% year-over-year to $240.7 million, compared with a TTM value of $240.7 million through Dec 2019, up 26.07%, and an annual FY2019 reading of $243.5 million, up 23.25% over the prior year.
  • Common Equity was $240.7 million for Q4 2019 at Innate Pharma, up from $190.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $240.7 million in Q4 2019 and bottomed at $101.2 million in Q4 2017.
  • Average Common Equity over 3 years is $177.6 million, with a median of $190.9 million recorded in 2018.
  • The sharpest move saw Common Equity soared 88.61% in 2018, then rose 26.07% in 2019.
  • Year by year, Common Equity stood at $101.2 million in 2017, then skyrocketed by 88.61% to $190.9 million in 2018, then rose by 26.07% to $240.7 million in 2019.
  • Business Quant data shows Common Equity for IPHA at $240.7 million in Q4 2019, $190.9 million in Q4 2018, and $101.2 million in Q4 2017.